Guido H. Wabnitz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Guido H. Wabnitz has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
Yvonne Samstag
University of Heidelberg
13 shared publicationsHenning Kirchgessner
Institute of Immunology, Section Molecular Immunology, Heidelberg University, Heidelberg, Germany
7 shared publications- Yvonne Samstag
Section Molecular Immunology, Institute of Immunology, Heidelberg University Hospital, Heidelberg, Germany
6 shared publications - Emre Balta
Section Molecular Immunology, Institute of Immunology, Heidelberg University, Heidelberg, Germany
5 shared publications Jüri Habicht
University of Heidelberg
4 shared publicationsBeate Jahraus
Institute of Immunology, Ruprecht Karls University
3 shared publications
Latest Publications
- Open Access
- 24 July 2026
- Published by Elsevier in Trends Open
- Vol. 1 (4) , 818-834
From destructive inflammation to redox-governed reparative immunity
- 24 July 2026
- Published by Elsevier in Trends Open
- Vol. 1 (4) , 818-834
Open AccessFrom destructive inflammation to redox-governed reparative immunity
- Open Access
- 22 June 2026
- Published by Elsevier in Cell Reports
- Vol. 45 (7) , 117563
Mrgpra2+ neutrophils stand guard in the infected bone marrow
- 22 June 2026
- Published by Elsevier in Cell Reports
- Vol. 45 (7) , 117563
Open AccessMrgpra2+ neutrophils stand guard in the infected bone marrow
- Open Access
- 21 April 2026
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 13 (6) , 1303-1304
Reply to Letter: “Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring” by Saccà and Pelto Regarding “Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab”
- 21 April 2026
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 13 (6) , 1303-1304
Open AccessReply to Letter: “Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring” by Saccà and Pelto Regarding “Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab”
- Open Access
- 19 November 2025
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 13 (4) , 688-699
Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab
Objective: To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab. Methods: In this prospective, exploratory real‐world study CH50 and AH50, eculizumab and ravulizumab blood levels were assessed in patients with acetylcholine‐receptor‐antibody (AChR‐ab) positive gMG. Patients were either pretreated with eculizumab or C5‐inhibitor naïve. Samples were collected before the next infusion (end‐of‐dose). Laboratory data were correlated with patient‐reported subjective duration of the ravulizumab effect. Results: Overall, 61 patients were enrolled. At the end of their respective dosing interval, median AH50 levels were more strongly suppressed with eculizumab than with ravulizumab (1% [0%–2%] versus 5% [3%–9%]; Cohen's d 2.2 [95% CI 1.5–2.8]). Patients who discontinued ravulizumab due to insufficient effects ( n = 19; 33%) had higher median AH50 levels than those who continued (7% [4%–13%] versus 5% [3%–8%]; Cohen's d −0.9 [95% CI −1.3 to −0.4]). In 81% ( n = 46) of patients, the therapeutic effect of ravulizumab diminished before the subsequent infusion after the standard 8‐week interval. Higher AH50 levels were correlated with earlier symptom recurrence. Interpretation: Our results indicate potential differences in the ability of eculizumab and ravulizumab to suppress complement pathway activity through their respective dosing intervals. Additionally, higher AH50 levels might be a potential biomarker to predict poor therapy response and faster wearing off of ravulizumab's effect. However, these findings need to be validated in large multicenter studies.
- 19 November 2025
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 13 (4) , 688-699
Open AccessInhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab
Objective: To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab. Methods: In this prospective, exploratory real‐world study CH50 and AH50, eculizumab and ravulizumab blood levels were assessed in patients with acetylcholine‐receptor‐antibody (AChR‐ab) positive gMG. Patients were either pretreated with eculizumab or C5‐inhibitor naïve. Samples were collected before the next infusion (end‐of‐dose). Laboratory data were correlated with patient‐reported subjective duration of the ravulizumab effect. Results: Overall, 61 patients were enrolled. At the end of their respective dosing interval, median AH50 levels were more strongly suppressed with eculizumab than with ravulizumab (1% [0%–2%] versus 5% [3%–9%]; Cohen's d 2.2 [95% CI 1.5–2.8]). Patients who discontinued ravulizumab due to insufficient effects ( n = 19; 33%) had higher median AH50 levels than those who continued (7% [4%–13%] versus 5% [3%–8%]; Cohen's d −0.9 [95% CI −1.3 to −0.4]). In 81% ( n = 46) of patients, the therapeutic effect of ravulizumab diminished before the subsequent infusion after the standard 8‐week interval. Higher AH50 levels were correlated with earlier symptom recurrence. Interpretation: Our results indicate potential differences in the ability of eculizumab and ravulizumab to suppress complement pathway activity through their respective dosing intervals. Additionally, higher AH50 levels might be a potential biomarker to predict poor therapy response and faster wearing off of ravulizumab's effect. However, these findings need to be validated in large multicenter studies.
- Open Access
Accurate, fast and memory efficient quantification of immune cell phenotypes in cytometry using machine learning
To achieve accurate and reproducible cytometry data analysis, we benchmarked 19 machine learning algorithms for supervised and unsupervised cell classification. The underlying data encompassed 138 million cells from seven independent datasets including conventional flow cytometry, spectral flow cytometry and mass cytometry. We found that tree-based classifiers and in particular Decision Trees, outperformed other approaches in classification accuracy, speed and memory use. High accuracy was achieved even for cell populations rarer than 1% using decision trees. We validated our decision tree-based approach in a clinical setting using diagnostic blood T cell phenotyping of 107 patients. Automatic quantification of CD4 helper T cell phenotypes achieved 99 % accuracy compared to manual expert assessment. Finally, we combined automated data transformation, supervised and unsupervised gating, an application program interface and a user-friendly desktop-application into FACSPy and FACSPyUI, a fast and scalable open-source toolbox for the analysis and visualization of cytometry data.
Open AccessAccurate, fast and memory efficient quantification of immune cell phenotypes in cytometry using machine learning
To achieve accurate and reproducible cytometry data analysis, we benchmarked 19 machine learning algorithms for supervised and unsupervised cell classification. The underlying data encompassed 138 million cells from seven independent datasets including conventional flow cytometry, spectral flow cytometry and mass cytometry. We found that tree-based classifiers and in particular Decision Trees, outperformed other approaches in classification accuracy, speed and memory use. High accuracy was achieved even for cell populations rarer than 1% using decision trees. We validated our decision tree-based approach in a clinical setting using diagnostic blood T cell phenotyping of 107 patients. Automatic quantification of CD4 helper T cell phenotypes achieved 99 % accuracy compared to manual expert assessment. Finally, we combined automated data transformation, supervised and unsupervised gating, an application program interface and a user-friendly desktop-application into FACSPy and FACSPyUI, a fast and scalable open-source toolbox for the analysis and visualization of cytometry data.
- Open Access
- 8 December 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-21
Human and mouse neutrophils share core transcriptional programs in both homeostatic and inflamed contexts
Neutrophils are frequently studied in mouse models, but the extent to which findings translate to humans remains poorly defined. In an integrative analysis of 11 mouse and 13 human datasets, we find a strong correlation of neutrophil gene expression across species. In inflammation, neutrophils display substantial transcriptional diversity but share a core inflammation program. This program includes genes encoding IL-1 family members, CD14, IL-4R, CD69, and PD-L1. Chromatin accessibility of core inflammation genes increases in blood compared to bone marrow and further in tissue. Transcription factor enrichment analysis implicates members of the NF-κB family and AP-1 complex as important drivers, and HoxB8 neutrophils with JunB knockout show a reduced expression of core inflammation genes in resting and activated cells. In independent single-cell validation data, neutrophil activation by type I or type II interferon, G-CSF, and E. coli leads to upregulation in core inflammation genes. In COVID-19 patients, higher expression of core inflammation genes in neutrophils is associated with more severe disease. In vitro treatment with GM-CSF, LPS, and type II interferon induces surface protein upregulation of core inflammation members. Together, we demonstrate transcriptional conservation in neutrophils in homeostasis and identify a core inflammation program shared across heterogeneous inflammatory conditions.
- 8 December 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-21
Open AccessHuman and mouse neutrophils share core transcriptional programs in both homeostatic and inflamed contexts
Neutrophils are frequently studied in mouse models, but the extent to which findings translate to humans remains poorly defined. In an integrative analysis of 11 mouse and 13 human datasets, we find a strong correlation of neutrophil gene expression across species. In inflammation, neutrophils display substantial transcriptional diversity but share a core inflammation program. This program includes genes encoding IL-1 family members, CD14, IL-4R, CD69, and PD-L1. Chromatin accessibility of core inflammation genes increases in blood compared to bone marrow and further in tissue. Transcription factor enrichment analysis implicates members of the NF-κB family and AP-1 complex as important drivers, and HoxB8 neutrophils with JunB knockout show a reduced expression of core inflammation genes in resting and activated cells. In independent single-cell validation data, neutrophil activation by type I or type II interferon, G-CSF, and E. coli leads to upregulation in core inflammation genes. In COVID-19 patients, higher expression of core inflammation genes in neutrophils is associated with more severe disease. In vitro treatment with GM-CSF, LPS, and type II interferon induces surface protein upregulation of core inflammation members. Together, we demonstrate transcriptional conservation in neutrophils in homeostasis and identify a core inflammation program shared across heterogeneous inflammatory conditions.
- Open Access
Distinct Functional States of Neutrophils by Actin Disassembly and NF-kB/STAT3 Signaling
Polymorphonuclear neutrophils (PMNs) can differentiate into distinct states, which can either exacerbate or resolve inflammation. Our study shows that mice challenged with TLR agonists exhibited PMN differentiation along two major paths characterized by the expression of CCR5 or PD-L1. Similar differentiation was observed in the blood of severe COVID-19 patients and the synovial fluid of osteoarthritis patients. Prolonged in vitro priming of human PMNs modeled the differentiation paths. Actin disassembly favored CCR5 upregulation, while NF-kB activation stabilized the actin cytoskeleton and suppressed the development of CCR5 + PMNs. Additionally, PD-L1 upregulation was triggered by STAT3 signaling and NF-kB activation. Functionally, CCR5 expressing PMNs were pro-NETotic, while PD-L1 + PMNs showed immunosuppressive functions by inhibiting T cell proliferation via PD1. Together, PMN differentiation depended on the priming conditions, and the balance between actin disassembly and NF-kB/STAT3 activation translated the present micro-milieu into phenotypic and functional diversification of PMNs. Synopsis: Neutrophils underwent phenotypical and functional diversification both in vivo and in vitro . Actin disassembly led to the generation of CCR5 high neutrophils with increased spontaneous NETosis, whereas NF-kB and STAT3 induced PD-L1 expression with T-cell suppressive properties as a deviation from the default pathway. PMN of mice challenged with TLR agonists develop two distinct phenotypes, CCR5 high and PD-L1 high . CCR5 and PD-L1-defined neutrophil phenotypes were found in blood of patients with severe COVID-19 and in the synovial fluid of osteoarthritis patients. In vitro priming induced a similar bifurcation of PMN phenotypes marked by either CCR5 or PD-L1. Actin disassembly preceded canonical development of CCR5 + PMN. NF-kB halted actin disassembly by LPL regulation. During neutrophil priming, STAT3 aided NF-kB in the expression of PD-L1. Graphical
Open AccessDistinct Functional States of Neutrophils by Actin Disassembly and NF-kB/STAT3 Signaling
Polymorphonuclear neutrophils (PMNs) can differentiate into distinct states, which can either exacerbate or resolve inflammation. Our study shows that mice challenged with TLR agonists exhibited PMN differentiation along two major paths characterized by the expression of CCR5 or PD-L1. Similar differentiation was observed in the blood of severe COVID-19 patients and the synovial fluid of osteoarthritis patients. Prolonged in vitro priming of human PMNs modeled the differentiation paths. Actin disassembly favored CCR5 upregulation, while NF-kB activation stabilized the actin cytoskeleton and suppressed the development of CCR5 + PMNs. Additionally, PD-L1 upregulation was triggered by STAT3 signaling and NF-kB activation. Functionally, CCR5 expressing PMNs were pro-NETotic, while PD-L1 + PMNs showed immunosuppressive functions by inhibiting T cell proliferation via PD1. Together, PMN differentiation depended on the priming conditions, and the balance between actin disassembly and NF-kB/STAT3 activation translated the present micro-milieu into phenotypic and functional diversification of PMNs. Synopsis: Neutrophils underwent phenotypical and functional diversification both in vivo and in vitro . Actin disassembly led to the generation of CCR5 high neutrophils with increased spontaneous NETosis, whereas NF-kB and STAT3 induced PD-L1 expression with T-cell suppressive properties as a deviation from the default pathway. PMN of mice challenged with TLR agonists develop two distinct phenotypes, CCR5 high and PD-L1 high . CCR5 and PD-L1-defined neutrophil phenotypes were found in blood of patients with severe COVID-19 and in the synovial fluid of osteoarthritis patients. In vitro priming induced a similar bifurcation of PMN phenotypes marked by either CCR5 or PD-L1. Actin disassembly preceded canonical development of CCR5 + PMN. NF-kB halted actin disassembly by LPL regulation. During neutrophil priming, STAT3 aided NF-kB in the expression of PD-L1. Graphical
- Open Access
Human and murine neutrophils share core transcriptional programs in both homeostatic and inflamed contexts
Neutrophils are frequently studied in murine models, but the extent to which findings translate to humans remains poorly defined. Here, we performed an integrative transcriptomic analysis of 11 murine and 13 human datasets. In homeostasis, neutrophils exhibited the highest number of lineage-specific genes and the greatest degree of correlated expression among genes with one-to-one orthologs ( r = 0.79, P < 2.2 × 10 −16 ) compared to other leukocytes. In inflammation, neutrophils displayed considerable transcriptional diversity, but shared a core inflammation program across a broad range of conditions which was conserved between species. This core program included genes encoding IL-1 family members, CD14, IL-4R, CD69 and PD-L1. Chromatin accessibility of core inflammation genes increased significantly in blood compared to bone marrow and further with migration from blood to tissue. Transcription factor enrichment analysis nominated members of the NF-κB family and AP-1 complex as important drivers of the core inflammation program, and HoxB8 neutrophils with JUNB knockout showed a significantly reduced expression of core inflammation genes at baseline and upon stimulation. In vitro perturbations confirmed surface protein upregulation of core inflammation members in both species. Together, we demonstrate substantial transcriptional conservation in neutrophils in homeostasis and identify a core inflammation program conserved across species. This systems biology approach can be leveraged to improve transitions between the murine and human context. Key Points: The transcriptome of resting neutrophils is substantially conserved between humans and mice A core inflammation program in neutrophils is shared across a broad range of conditions and conserved across humans and mice Graphical
Open AccessHuman and murine neutrophils share core transcriptional programs in both homeostatic and inflamed contexts
Neutrophils are frequently studied in murine models, but the extent to which findings translate to humans remains poorly defined. Here, we performed an integrative transcriptomic analysis of 11 murine and 13 human datasets. In homeostasis, neutrophils exhibited the highest number of lineage-specific genes and the greatest degree of correlated expression among genes with one-to-one orthologs ( r = 0.79, P < 2.2 × 10 −16 ) compared to other leukocytes. In inflammation, neutrophils displayed considerable transcriptional diversity, but shared a core inflammation program across a broad range of conditions which was conserved between species. This core program included genes encoding IL-1 family members, CD14, IL-4R, CD69 and PD-L1. Chromatin accessibility of core inflammation genes increased significantly in blood compared to bone marrow and further with migration from blood to tissue. Transcription factor enrichment analysis nominated members of the NF-κB family and AP-1 complex as important drivers of the core inflammation program, and HoxB8 neutrophils with JUNB knockout showed a significantly reduced expression of core inflammation genes at baseline and upon stimulation. In vitro perturbations confirmed surface protein upregulation of core inflammation members in both species. Together, we demonstrate substantial transcriptional conservation in neutrophils in homeostasis and identify a core inflammation program conserved across species. This systems biology approach can be leveraged to improve transitions between the murine and human context. Key Points: The transcriptome of resting neutrophils is substantially conserved between humans and mice A core inflammation program in neutrophils is shared across a broad range of conditions and conserved across humans and mice Graphical
- Open Access
- 19 April 2022
- Published by Elsevier in Cell Reports
- Vol. 39 (3) , 110710
Inflammation induces pro-NETotic neutrophils via TNFR2 signaling
- 19 April 2022
- Published by Elsevier in Cell Reports
- Vol. 39 (3) , 110710
Open AccessInflammation induces pro-NETotic neutrophils via TNFR2 signaling
- Open Access
Inflammation induces pro-NETotic neutrophils via TNFR2 signaling
Cytokines released during chronic inflammatory diseases induce pro-inflammatory properties in polymorphonuclear neutrophils (PMN). Here we show that in vitro cytokine treatment leads to the development of a subgroup of human PMN expressing CCR5, termed CCR5 + cytokine-induced PMN (CCR5 + cPMN). Auto/paracrine TNF signaling increases intracellular neutrophil elastase (ELANE) abundance and induces NETosis in CCR5 + cPMN. Triggering of CCR5 amplifies NETosis. Membranous TNF (mTNF) outside-in signaling induces the formation of reactive oxygen species, a known activator of NETosis. In vivo , we find an increased number of CCR5 + cPMN in the peripheral blood and inflamed lamina propria of patients with ulcerative colitis (UC) but not Crohn’s disease (CD). Notably, failure of anti-TNF therapy is associated with higher frequencies of CCR5 + cPMN. In conclusion, we identify a phenotype of pro-NETotic, CCR5 positive PMN present in inflamed tissue in vivo and inducible in vitro . These cells may reflect an important component of tissue damage during chronic inflammation and could be of diagnostic value.
Open AccessInflammation induces pro-NETotic neutrophils via TNFR2 signaling
Cytokines released during chronic inflammatory diseases induce pro-inflammatory properties in polymorphonuclear neutrophils (PMN). Here we show that in vitro cytokine treatment leads to the development of a subgroup of human PMN expressing CCR5, termed CCR5 + cytokine-induced PMN (CCR5 + cPMN). Auto/paracrine TNF signaling increases intracellular neutrophil elastase (ELANE) abundance and induces NETosis in CCR5 + cPMN. Triggering of CCR5 amplifies NETosis. Membranous TNF (mTNF) outside-in signaling induces the formation of reactive oxygen species, a known activator of NETosis. In vivo , we find an increased number of CCR5 + cPMN in the peripheral blood and inflamed lamina propria of patients with ulcerative colitis (UC) but not Crohn’s disease (CD). Notably, failure of anti-TNF therapy is associated with higher frequencies of CCR5 + cPMN. In conclusion, we identify a phenotype of pro-NETotic, CCR5 positive PMN present in inflamed tissue in vivo and inducible in vitro . These cells may reflect an important component of tissue damage during chronic inflammation and could be of diagnostic value.